Breast Cancer | Current Treatment: Physician Insights | US | 2024
The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line treatments for metastatic HR-positive / HER2-negative disease; this drug class moved to the early-stage setting with the approval of adjuvant Verzenio in 2021. Biomarker-driven therapies—including Menarini Group’s Orserdu (ESR1-mutant), Novartis’s Piqray (PIK3CA-mutant), and AstraZeneca’s Truqap (PIK3CA/AKT1/PTEN-mutant)—have expanded the treatment options for metastatic HR-positive / HER2-negative disease. In triple-negative disease, Merck & Co.’s Keytruda has changed the treatment paradigm for some patients with early and metastatic breast cancer. PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza, Pfizer’s Talzenna) are an option in PARP-mutant patients with either triple-negative or HR-positive / HER2-negative disease; in these two subtypes, the approval of next-generation ADCs (Gilead’s Trodelvy and Daiichi Sankyo / AstraZeneca’s Enhertu for HER2-low disease) has diversified the therapy options for metastatic patients. In the HER2-positive metastatic setting, Enhertu’s label expansion to the second-line setting is redefining the treatment algorithm.
QUESTIONS ANSWERED
- What are the treatment rates for breast cancer across key subtypes and lines of therapy?
- What are the testing rates for select biomarkers (e.g., mutations in PIK3CA, ESR1, and PARP; HER2-low expression) in relevant breast cancer subtypes?
- What is the patient share of key drugs and regimens across breast cancer subtypes?
- What are the main drivers of, and key obstacles to, the uptake of select therapies?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 101 medical oncologists in the United States fielded in May 2024.
Key drugs: Ibrance, Kisqali, Verzenio, Lynparza, Piqray, Talzenna, Afinitor, fulvestrant, Orserdu, Trodelvy, Truqap, Keytruda, Perjeta, Tukysa, Phesgo, Enhertu, Tykerb, Nerlynx, and Kadcyla.
